SCHEMBL330186

SCHEMBL330186

[NH]C(=S)Nc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
TAS2R38 P59533 3/20 0.64
HSD17B10 Q99714 2/20 0.64
CYP3A4 P08684 1/20 0.64
GAA P10253 7/20 0.58
KMT2A Q03164 4/20 0.58
MEN1 O00255 2/20 0.58
RAB9A P51151 2/20 0.58
TP53 P04637 2/20 0.58
TSHR P16473 2/20 0.58
NOX1 Q9Y5S8 2/20 0.58
NPC1 O15118 1/20 0.58
TYR P14679 1/20 0.58
PHGDH O43175 1/20 0.56
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
EPHX1 P07099 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3070807 0.78 ALDH1A1 (0.70) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL132620 0.78 ALDH1A1 (1.00) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL1936559 0.78 ALDH1A1 (0.70) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL5819282 0.76 HSD17B10 (0.52) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL7670418 0.76 ALDH1A1 (0.67) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL9470190 0.76 ALDH1A1 (0.94) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL8956322 0.76 ALDH1A1 (0.94) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
Hydrochloric Acid SCHEMBL11243942 0.76 ALDH1A1 (0.67) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
Fluoride SCHEMBL28728322 0.76 ALDH1A1 (0.67) ALDH1A1TAS2R38HSD17B10CYP3A4GAA
SCHEMBL1466506 0.75 MDM2 (0.54) ALDH1A1GAAKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700655-B2 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-04-20 US claimed
US-7494815-B2 Method and apparatus for analyzing compounds with amino group AJINOMOTO CO., INC. (JP) 2009-02-24 US claimed
US-20080311074-A1 Inhibitors against activation of NF-kappaB INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) 2008-12-18 US claimed
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) 2008-09-25 US claimed
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals NOVARTIS AG (CH) 2008-08-14 US claimed
US-20080090779-A1 ANTIALLERGIC AGENTS INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-04-17 US claimed
US-20070269899-A1 METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP AJINOMOTO CO. INC. (JP) 2007-11-22 US claimed
US-20070185059-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US claimed
US-20070185110-A1 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2007-08-09 US claimed
EP-1758849-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS Novartis AG (CH) 2007-03-07 EP claimed
EP-0752986-A1 N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1997-01-15 EP claimed
EP-0749964-A1 N-Heterocyclyl biphenyl sulfonamides ZENECA LIMITED (GB) 1996-12-27 EP claimed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 WO claimed
EP-0687473-A1 OPTICAL ISOMERIZATION INHIBITOR FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-12-20 EP claimed
EP-0682016-A1 Pyridine derivatives ZENECA LIMITED (GB) 1995-11-15 EP claimed
WO-1995026957-A1 N-HETEROCYCLYL SULPHONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1995-10-12 WO claimed
US-5270213-A Protein sequencing PORTON INSTRUMENTS, INC. (US) 1993-12-14 US claimed
EP-0360079-A1 Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-03-28 EP claimed
US-4865994-A REACTING 2-ANILINO-S-THIAZOLINONE MODIFIED AMINO ACID WITH AMINO COMPOUND LABELED WITH RADIOACTIVE ISOTOPE SEIKO INSTRUMENTS & ELECTRONICS LTD. (JP) 1989-09-12 US claimed
EP-0005507-A1 Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby CIBA-GEIGY AG (CH) 1979-11-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311074-A1 Inhibitors against activation of NF-kappaB NFKBIA, IKBKB, RELA ALDH1A1 2096/4885TAS2R38 4858/4885HSD17B10 2440/4885
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals MB, ACHE, ADORA2B ALDH1A1 90/4885TAS2R38 4446/4885HSD17B10 2142/4885
US-20080090779-A1 ANTIALLERGIC AGENTS NAT1, EPX, HRH2 ALDH1A1 364/4885TAS2R38 4295/4885HSD17B10 761/4885
US-20080234233-A1 MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAPT, TFEB, MAOA ALDH1A1 425/4885TAS2R38 3896/4885HSD17B10 1152/4885
US-20070185110-A1 Antiallergic agents NAT1, EPX, AHR ALDH1A1 340/4885TAS2R38 4203/4885HSD17B10 855/4885
US-20070185059-A1 Antiallergic agents NAT1, EPX, AHR ALDH1A1 362/4885TAS2R38 4280/4885HSD17B10 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.